Market Place
Sourcing Support
Femasys Launches Femaseed Complete For OB/GYNs At ACOG 2026
22 Apr 2026 //
GLOBENEWSWIRE
Femasys Appoints John Canning COO to Drive Execution & Growth
01 Apr 2026 //
GLOBENEWSWIRE
Femasys Reveals 2025 Financial Results And Corporate Update
31 Mar 2026 //
GLOBENEWSWIRE
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors
18 Mar 2026 //
GLOBENEWSWIRE
Femasys Progresses Fembloc For U.S. Approval With Pivotal Trial
10 Mar 2026 //
GLOBENEWSWIRE
Femasys Reveals Inducement Grants Per Nasdaq LR 5635(C)(4)
27 Feb 2026 //
GLOBENEWSWIRE
Femasys Advances Global Access With Fembloc MDSAP Certification
26 Feb 2026 //
GLOBENEWSWIRE
Femasys Secures CPT Code for FemaSeed
23 Feb 2026 //
GLOBENEWSWIRE
Femasys Inks Swiss Deal for FemBloc, FemaSeed, Portfolio Products
03 Feb 2026 //
GLOBENEWSWIRE
Femasys Receives 180-Day Nasdaq Extension For Bid Price
14 Jan 2026 //
GLOBENEWSWIRE
Femasys Partners With Refuah Health to Expand FemaSeed Access
13 Jan 2026 //
GLOBENEWSWIRE
Femasys Gets FDA Clearance For Next-Gen Femvue Diagnostic Device
18 Dec 2025 //
GLOBENEWSWIRE
Pharmacyte Bio Monetizes Femasys Stake, Boosts Cash And Strategy
25 Nov 2025 //
BUSINESSWIRE
Femasys Announces Third Quarter Financial Results For 2025
14 Nov 2025 //
GLOBENEWSWIRE
Femasys Boosts Global Expansion With Second Fembloc Order
10 Nov 2025 //
GLOBENEWSWIRE
Femasys Gets FDA Nod to Begin Final FemBloc Ph, Secures $12M
03 Nov 2025 //
GLOBENEWSWIRE
Femasys Starts Post-Market Study For Fembloc® Birth Control
22 Oct 2025 //
GLOBENEWSWIRE
Femasys To Exhibit At The ASRM 2025 Scientific Congress & Expo
16 Oct 2025 //
GLOBENEWSWIRE
Femasys Expedites Fembloc® European Expansion Via Kebomed
25 Sep 2025 //
GLOBENEWSWIRE
Femasys, Medical Electronic Systems Launch Femsperm™ Kit
22 Sep 2025 //
GLOBENEWSWIRE
Femasys Launches New Insemination Prep Kit in FemSperm™ Line
11 Sep 2025 //
GLOBENEWSWIRE
Femasys Gets FemBloc® Birth Control Approval in New Zealand
08 Sep 2025 //
GLOBENEWSWIRE
Femasys Secures $8M for Fertility and Birth Control Launch
02 Sep 2025 //
GLOBENEWSWIRE
Femasys Launch FemSperm Kit to Boost FemaSeed Fertility Platform
21 Aug 2025 //
GLOBENEWSWIRE
Femasys Gets UK Approval for FemBloc Birth Control
20 Aug 2025 //
GLOBENEWSWIRE
Femasys Reveals Q2 Financial Results for 2025
08 Aug 2025 //
GLOBENEWSWIRE
Femasys Secures First EU Order for FemBloc in Global Expansion
06 Aug 2025 //
GLOBENEWSWIRE
Femasys gets Australian, New Zealand approvals for FemaSeed®
01 Jul 2025 //
GLOBENEWSWIRE
FemBloc Gets EU Nod as First Non-Surgical Birth Control Option
25 Jun 2025 //
GLOBENEWSWIRE
Femasys Partners With Carolinas Fertility to Offer FemaSeed
11 Jun 2025 //
GLOBENEWSWIRE
Femasys Prices Public Offering and Private Placement at $4.5M
30 May 2025 //
GLOBENEWSWIRE
Femasys Plans Public Stock Offering with Private Placement
29 May 2025 //
GLOBENEWSWIRE
Femasys Reports Q1 2025 Financials and Corporate Update
08 May 2025 //
GLOBENEWSWIRE
Femasys Announces 2024 Financial Results and Corporate Update
27 Mar 2025 //
GLOBENEWSWIRE
Femasys Partners With CNY Fertility To Offer FemaSeed
19 Mar 2025 //
GLOBENEWSWIRE
Femasys Secures Distribution Partnerships for FemBloc® in Spain
18 Mar 2025 //
GLOBENEWSWIRE
Femasys Announces FemBloc Approval in Europe for Permanent Birth
13 Mar 2025 //
GLOBENEWSWIRE
Femasys Announces Positive Safety and Efficacy Results from FemBl
25 Feb 2025 //
GLOBENEWSWIRE
Femasys Gets UK Nod For FemaSeed, Two Diagnostic Devices
11 Feb 2025 //
GLOBENEWSWIRE
Femasys Announces Israeli Approvals for FemaSeed® & 2 Diagnostic
04 Feb 2025 //
GLOBENEWSWIRE
Femasys Granted Two European Patents For FemBloc Birth Control
30 Jan 2025 //
GLOBENEWSWIRE
Femasys Receives US Patent Allowance For FemaSeed® Infertility Use
16 Jan 2025 //
GLOBENEWSWIRE
Femasys Partners with HRC Fertility to Offer FemaSeed
03 Dec 2024 //
GLOBENEWSWIRE
Femasys Publishes Positive Data from FemaSeed® Infertility Trial
26 Nov 2024 //
GLOBENEWSWIRE
Femasys Announces Financial Results for Quarter Ended Sept 30
12 Nov 2024 //
GLOBENEWSWIRE
Femasys to Exhibit at Annual AAGL 2024 Global Conference
07 Nov 2024 //
GLOBENEWSWIRE
Femasys Announces U.S. Patent for FemBloc® Permanent Birth Control
01 Nov 2024 //
GLOBENEWSWIRE
Femasys Partners with Boston IVF for FemaSeed Offering
30 Oct 2024 //
GLOBENEWSWIRE
Femasys To Exhibit At ASRM 2024 And Join KEEPR Education Program
10 Oct 2024 //
GLOBENEWSWIRE
Femasys To Participate In Maxim Healthcare Virtual Summit
08 Oct 2024 //
GLOBENEWSWIRE
Femasys Gets Second Order from Spain for FemaSeed®
02 Oct 2024 //
GLOBENEWSWIRE
Femasys Announces Infertility Clinic Customers from Coast to Coast
18 Sep 2024 //
GLOBENEWSWIRE
Femasys Secures $1.3M Distribution Deal For FemaSeed In Spanish Market
11 Sep 2024 //
GLOBENEWSWIRE
Femasys Receives FDA Clearance For FemChec
09 Sep 2024 //
GLOBENEWSWIRE
Femasys To Exhibit At Canadian Fertility Society Meeting
05 Sep 2024 //
GLOBENEWSWIRE
Femasys to Join Fireside Chat at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Femasys Gets CE Mark and Canadian Approval for FemVue® MINI Assessment Solution
29 Aug 2024 //
GLOBENEWSWIRE
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
27 Aug 2024 //
GLOBENEWSWIRE
Femasys Announces Q2 2024 Results And Provides Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Femasys to Participate in European Society of Human Reproduction and Embryology
27 Jun 2024 //
GLOBENEWSWIRE
